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Glaucoma is a group of optic neuropathies associated with aging and sensitivity to
intraocular pressure (IOP). The disease is the leading cause of irreversible blindness
worldwide. Early progression in glaucoma involves dysfunction of retinal ganglion cell
(RGC) axons, which comprise the optic nerve. Deficits in anterograde transport along
RGC axons to central visual structures precede outright degeneration, and preventing
these deficits is efficacious at abating subsequent progression. HE3286 is a synthetic
sterol derivative that has shown therapeutic promise in models of inflammatory disease
and neurodegenerative disease. We examined the efficacy of HE3286 oral delivery in
preventing loss of anterograde transport in an inducible model of glaucoma (microbead
occlusion). Adult rats received HE3286 (20 or 100 mg/kg) or vehicle daily via oral
gavage for 4 weeks. Microbead occlusion elevated IOP ∼30% in all treatment groups,
and elevation was not affected by HE3286 treatment. In the vehicle group, elevated
IOP reduced anterograde axonal transport to the superior colliculus, the most distal
site in the optic projection, by 43% (p = 0.003); HE3286 (100 mg/kg) prevented this
reduction (p = 0.025). HE3286 increased brain-derived neurotrophic factor (BDNF) in
the optic nerve head and retina, while decreasing inflammatory and pathogenic proteins
associated with elevated IOP compared to vehicle treatment. Treatment with HE3286
also increased nuclear localization of the transcription factor NFκB in collicular and
retinal neurons, but decreased NFκB in glial nuclei in the optic nerve head. Thus,
HE3286 may have a neuroprotective influence in glaucoma, as well as other chronic
neurodegenerations.
Keywords: glaucoma, neuroinflammation, neuroprotection, axonopathy, HE3286, NF kappa B, axonal transport,
brain derived neurotrophic factor
INTRODUCTION
Glaucoma is the leading cause of irreversible blindness worldwide (Quigley and Broman, 2006). The
disease selectively targets retinal ganglion cells (RGCs) and their axons through stress conveyed at
the optic nerve head (Calkins, 2012; Nickells et al., 2012). Age is a major risk factor for developing
glaucoma, but sensitivity to intraocular pressure (IOP) is the only modifiable risk factor and sole
target for clinical intervention (Heijl et al., 2002). Decreasing IOP with drugs or surgery can slow
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disease progression, but for many patients does not prevent
RGC degeneration and vision loss (Heijl et al., 2002). Given
that by 2020 nearly 80 million people will have glaucoma,
with an estimated 11.2 million with permanent vision loss
(Quigley and Broman, 2006; Cheung et al., 2008; Schober
et al., 2008), the identification of therapeutic agents that
can protect RGCs independently of IOP is of paramount
importance.
HE3286 (17α-Ethynyl-androst-5ene-3β, 7β, 17β-triol) is a
synthetic derivative of androst-5-ene-3β,7β,17β-triol (AET), a
non-glucocorticoid anti-inflammatory metabolite of the adrenal
steroid, dehydroepiandrosterone (DHEA; Ahlem et al., 2011).
DHEA and AET have shown therapeutic promise in rodent
models of immune-mediated inflammatory disorders with
varying results in clinical trials (Offner et al., 2002; Dillon, 2005;
Ahlem et al., 2009). HE3286 shows better oral bioavailability
in humans, has low potential for toxicity, does not bind to
glucocorticoid receptor or any known nuclear hormone receptor,
and is not immunosuppressive (Wang et al., 2010; Ahlem et al.,
2011). Treatment with HE3286 improves outcome measures in
models of autoimmune disease, lung inflammation, experimental
optic neuritis and Parkinson’s disease, and is currently being
tested in clinical trials (Auci et al., 2007, 2010; Ahlem et al., 2009;
Offner et al., 2009; Conrad et al., 2010; Lu et al., 2010; Kosiewicz
et al., 2011; Nicoletti et al., 2012; Reading et al., 2013a,b; Khan
et al., 2014). It is believed HE3286 may act via binding, regulation
and/or activation of MAPK or ERK, or through modulation of
NFκB (Lu et al., 2010; Ahlem et al., 2011; Nicoletti et al., 2012;
Reading et al., 2012).
Neurodegeneration in glaucoma shows many similarities with
other age-related neurodegenerative disorders, including early
deficits in axon function that precede loss of neurons themselves
(Crish and Calkins, 2011; Mckinnon, 2012; Ghiso et al., 2013;
Jindal, 2013; Danesh-Meyer and Levin, 2015; Jain and Aref,
2015). In animal models of glaucoma, degradation of RGC
anterograde transport to central brain targets occurs early and
prior to outright loss of axons in the optic projection (Crish
et al., 2010, 2013; Dengler-Crish et al., 2014). Experimental
interventions that prevent transport deficits are efficacious at
stopping subsequent degeneration of axons and cell bodies
(Lambert et al., 2011; Dapper et al., 2013). Here, we tested
whether HE3286 could rescue RGC axon transport andmodulate
markers for neuroinflammation in the optic projection using
our inducible microbead occlusion model of glaucoma in rats
(Crish et al., 2010; Sappington et al., 2010; Dapper et al., 2013).
We found that while HE3286 had no effect on IOP, daily oral
delivery for 4 weeks prevented deficits in anterograde transport
to the superior colliculus (SC), the primary central projection
for RGCs in rodents (Linden and Perry, 1983; Hofbauer and
Drager, 1985). HE3286 also influenced the level of many
proteins implicated in the pathogenesis of glaucoma and other
neurodegenerative disorders throughout the optic projection.
Finally, HE3286 increased activation of the transcription factor
NFκB in colliculus and retina, while decreasing glial NFκB
activation in the optic nerve head, which is a major pathogenic
site of neuroinflammation in glaucoma (Soto and Howell, 2014;
Russo et al., 2016). These data suggest HE3286 has therapeutic
potential with regards to neurodegeneration in glaucoma by
modulating common neuroinflammatory pathways.
MATERIALS AND METHODS
Animals
All experimental procedures were conducted in accordance with
the guidelines of and approved by The Vanderbilt University
Institutional Animal Care and Use Committee. Brown Norway
rats (7–9 months old, male) were obtained from Charles River
Laboratories (Wilmington, MA) and maintained in a 12-h light-
dark cycle with standard rodent chow available ad libitum. Three
cohorts of rats (n = 6 per cohort; 18 rats total) were randomly
assigned to one of three treatment groups: vehicle, 20 mg/kg
HE3286 or 100 mg/kg HE3286. We measured IOP bilaterally in
awake rats using a TonoPen XL rebound tonometer (Medtronic
Solan, Jacksonville, FL) as previously described (Sappington et al.,
2010; Crish et al., 2013; Dapper et al., 2013). To avoid corneal
irritation, hydrating eye drops were administered to each eye
at the completion of IOP measurements. Prior to microbead
occlusion (Sappington et al., 2010; Crish et al., 2013; Dapper et al.,
2013), we monitored IOP for 2–3 days; these measurements were
averaged to obtain a baseline value. We elevated IOP unilaterally
(OS) by a single 5.0µl injection of 15µmpolystyrenemicrobeads
(Molecular Probes, Eugene, OR) into the anterior chamber. The
fellow eye (OD) received an equivalent volume of saline to serve
as an internal control. Beginning 24 h post-injection (day 1),
we monitored IOP using tonometry at least three times weekly
for the duration of the experiment (Sappington et al., 2010;
Crish et al., 2013; Dapper et al., 2013). Beginning with the
microbead injection (day 0), rats received 20 mg/kg or 100 mg/kg
HE3286 (10 mg/mL HE3286 in an aqueous medium containing
1 mg/mL sodium carboxymethyl cellulose, 9 mg/mL sodium
chloride, 20 mg/mL polysorbate-80, and 0.5 mg/mL phenol as
abroad spectrum preservative, Harbor Therapeutics, San Diego,
CA 92122) via oral gavage. For the vehicle group, half received
20 mg/kg vehicle and the other half 100 mg/kg vehicle (1 mg/mL
sodium carboxymethyl cellulose, 9 mg/mL sodium chloride, 20
mg/mL polysorbate-80, and 0.5 mg/mL phenol in an aqueous
medium, Harbor Therapeutics, San Diego, CA 92122). Rats
received vehicle or HE3286 once daily via oral gavage for 28 days.
Anterograde Axonal Transport
Forty-eight hours prior to perfusion, rats were anesthetized
with 2.5% isoflurane and injected intravitreally with 2 µl of
0.5mg cholera toxin subunit B (CTB) conjugated to Alexa
Fluor-488 (Molecular Probes, CA) as previously described (Crish
et al., 2010; Dapper et al., 2013; Ward et al., 2014). Animals
were transcardially perfused with phosphate buffered saline
(PBS) followed with 4% paraformaldehyde in PBS. Brains
were cryoprotected overnight in 30% sucrose/PBS and coronal
midbrain sections (50 µm) cut on a freezing sliding microtome.
Alternating sections of superior colliculus (SC) were imaged
using a Nikon Ti Eclipse microscope (Nikon Instruments Inc.,
Melville, NY) and the intensity of CTB signal was quantified
using a custom ImagePro macro (Media Cybernetics, Bethesda,
MD) as previously described (Crish et al., 2010; Dapper et al.,
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2013; Ward et al., 2014). After normalizing to background, CTB
signal intensity was calculated to reconstruct a retinotopic map
of intact anterograde transport across the SC. Percent of intact
transport for each map was defined as the region of the SC with
intensity ≥70% of the maximum CTB signal for that tissue. CTB
uptake by RGCs in the retina was verified using a Zeiss FV-1000
inverted confocal microscope through the Vanderbilt University
Medical Center Cell Imaging Shared Resource.
Immunohistochemistry
Whole eyes were dissected from perfused animals,
paraffin-embedded and vertically sectioned (6 µm).
Immunohistochemistry of whole eyes and brain was performed
as previously described and at identical conditions between
cohorts (Sappington et al., 2009; Crish et al., 2010; Weitlauf
et al., 2014). Primary antibodies used to immunolabel proteins
of interest in the brain, optic nerve head, and retina are listed
in Table 1. Sections were incubated with appropriate secondary
antibodies (1:200; Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA) and then cover-slipped with DAPI
Fluoromount G (Southern Biotech, Birmingham, AL). Sections
were imaged using a Zeiss FV-1000 inverted confocal microscope
through the Vanderbilt University Medical Center Cell Imaging
Shared Resource. For retina, all images were collected within
the mid-peripheral region for comparison across eyes and
cohorts. Identical microscope settings were used to acquire
images for signal quantification, which was performed by a
TABLE 1 | Primary antibodies used for brain and whole eye
immunohistochemistry.
Protein Dilution used Catalog number Vendor
Alzheimer precursor protein (APP) 1:50 MAB348 1
β-amyloid (Aβ) 1:200 #2454 2
Brain derived neurotrophic factor
(BDNF)
1:100 NBP2-42215 3
CD44 1:150 NB600-1317 3
C1q 1:1000 A301 4
Ceruloplasmin (Cp) 1:500 #611488 5
Choline acetyltransferase (ChAT) 1:100 AB144P 1
Glial fibrillary acidic protein (GFAP) 1:500 MAB360 1
Interleukin 1β (IL1β) 1:50 AF-501-NA 6
Interleukin 6 (IL6) 1:400 ab6672 7
IL6Rα membrane bound (IL6Rαm) 1:50 sc-600 8
Ionized Ca2+-binding adapter
molecule 1 (Iba1)
1:400 ab107159 7
NeuN 1:500 NBP1-92693 3
NF-κB 1:100 sc-372 8
p75 neurotrophin receptor (p75) 1:500 G323A 9
Phosphorylated neurofilament-H
(pNF-H)
1:1000 801601 10
Tumor necrosis factor α (TNFα) 1:300 AF-510-NA 6
1, EMD Millipore, Billerica, MA; 2, Cell Signaling Technology, Danvers, MA; 3, Novus
Biologicals, Littleton CO; 4, Quidel Corp., San Diego, CA; 5, BD Transductions Labs,
San Jose, CA; 6, R and D Systems, Minneapolis, MN; 7, AbCam, Cambridge, MA; 8,
Santa Cruz Biotechnologies, Dallas, TX; 9, Promega Corp., Madison, WI; 10, BioLegend,
San Diego, CA.
naïve observer using a custom macro in ImagePro (Media
Cybernetics; Bethesda, MD) that determines the percent area
of the positive label (Crish et al., 2013). The microbead to
saline ratio (microbead:saline) of label in a specific tissue was
calculated for each animal; ratios were averaged and reported
as label (microbead:saline). Nuclear localization of NFkB was
analyzed using a custom macro in ImageJ (Carmona et al.,
2007; Schneider et al., 2012) followed by signal quantification in
ImagePro. For quantifying label, a tissue section serving each
saline and microbead eye from at least five animals per cohort
was used. Retinal and nuclear layer thickness were measured at
five different retinal locations per image using the Measurement
tool in ImagePro. For RGC counts, the number of CTB-positive
and DAPI-positive cells within the ganglion cell layer were
counted using the Count tool in Photoshop. At least eight images
per animal were quantified to determine an average retinal
thickness.
Statistical Analysis
All data are expressed as mean± standard error unless indicated
otherwise. The number of samples used in each experiment is
provided in the appropriatemethods description or figure legend.
Statistical comparisons between two independent measurements
were made using two-sided t-tests, following confirmation of
normality for each using the Shapiro-Wilk normality test;
samples for which normality failed were compared using the
Mann-Whitney Rank Sum Test (SigmaPlot 12.5, Systat Software,
Inc., Chicago, IL). Comparisons between multiple groups were
made using one way analysis of variance (ANOVA) followed by
the Holm-Sidak Pairwise Multiple Comparison test (SigmaPlot
11.1, Systat Software, Inc., Chicago, IL). Comparisons of a sample
mean to a hypothesized or predicted value were made using
a one-sided t-test. Actual p-values of significance are indicated
where appropriate in the results section or figure legends. All
comparisons for which significance is reported achieved or
exceeded a post-hoc calculation of power of 0.80.
RESULTS
Two rats, one from each HE3286 group, were euthanized before
completion of the study due to complications from oral gavage.
Treatment with HE3286 for 28 days had few directly observable
adverse effects, as rats were active, responsive and showed no
overt signs of distress. HE3286 did result in weight loss in
both the 20 and 100 mg/kg groups (Table 2). Weights on day
0 (first day of treatment) ranged from 283 to 430 g, and mean
TABLE 2 | Weight loss with HE3286 treatment following microbead
injection.
Treatment group Weight day 0 (g) Weight day 28 (g) % Change (%)
Vehicle 357.2 ± 19.7 371.5 ± 21.0 +4.03
20 mg/kg HE3286 347.5 ± 6.5 326.3 ± 9.8 −6.16*
100 mg/kg HE3286 371.7 ± 15.0 333.7 ± 14.7 −10.26*†
*p < 0.001 compared to vehicle;
†
p = 0.042 compared to 20 mg/kg dose (n = 6 rats per
group).
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weights for the three treatment groups were not significantly
different (p = 0.523). Weights on day 28 (last day of treatment)
ranged from 290 to 440 g, with no significant difference in mean
weight between the three treatment groups (p= 0.130). However,
rats that received vehicle gained 14.3 g during the experimental
period, while rats that received 20 mg/kg HE3286 lost 21.2 g and
rats that received 100 mg/kg HE3286 lost 38.0 g. Comparing
percent change in weight over the course of treatment for each
animal showed that HE3286 decreased weight in both the 20
mg/kg group (p < 0.001, compared to vehicle) and 100 mg/kg
group (p< 0.001, compared to vehicle; p= 0.042 compared to 20
mg/kg).
Oral Delivery of HE3286 Has no Effect on
Ocular Pressure
Baseline IOP measurements ranged from 19.15 ± 0.50 to 20.29
± 0.55 mm Hg and were similar for all treatment groups (p =
0.638). Microbead injection elevated IOP in all eyes for the full
28 day period regardless of treatment (Figure 1A). In vehicle-
treated rats, elevation was 32.7% compared to saline-injected
eyes: 26.69± 2.73 vs. 20.12± 2.69mmHg; p= 0.002 (Figure 1B).
Similar increases of 29.6% and 30.0% were observed for the 20
mg/kg HE3286-treated group (26.39± 2.51 vs. 20.37± 2.68 mm
Hg, p = 0.002) and for the 100 mg/kg HE3286-treated group
(26.49 ± 2.52 vs. 20.39 ± 2.53 mm Hg, p = 0.002), respectively.
Mean IOP of saline eyes did not significantly differ for any
treatment group (p = 0.997); the same was true for microbead
eyes (p= 0.997).
HE3286 Rescues Anterograde Axonal
Transport to the Superior Colliculus
Deficits in anterograde axonal transport from retina to SC are
an early sign of pathogenesis in rodent models of glaucoma,
including microbead occlusion (Crish et al., 2010; Lambert et al.,
2011; Dapper et al., 2013; Ward et al., 2014). Figure 2 compares
the level of intact transport of fluorescently labeled CTB to the SC
of vehicle-, 20 mg/kg HE3286-, and 100 mg/kg HE3286-treated
rats. Deficits in transport are readily apparent in the SC from
microbead-injected eyes of vehicle rats (dotted lines, Figure 2A
top row). These deficits tend to fill in complete retinotopic
sectors when reconstructed from serial sections through the SC
(Figure 2A bottom row), consistent with our previous studies
(Lambert et al., 2011; Dapper et al., 2013). Variability in transport
was low in SC from saline-injected eyes (Figure 2B), which
had similarly intact transport for all groups: 89.2 ± 2.7% for
vehicle, 85.8 ± 3.9% for 20 mg/kg HE3286, and 90.9 ± 3.7% for
100 mg/kg HE3286 (Figure 2C; p = 0.593). Elevated IOP due
to microbead injection decreased intact transport to the SC in
vehicle-treated rats to 57.4± 6.0% intact transport (Figure 2C; p
= 0.003 compared to saline). Treatment with HE3286 attenuated
transport deficits dramatically, as intact transport to the SC from
microbead-injected eyes was 71.9 ± 9.8 and 83.0 ± 7.1% for
the 20 and 100 mg/kg HE3286 treatment groups, respectively
(Figure 2C); neither differed from intact transport from the
saline eye (p≥ 0.270). Compared to SC frommicrobead-injected
eyes in the vehicle group, the improvement was significant for
the 100 mg/kg HE3286 cohort (p = 0.025). No difference in
SC volume was detected for any groups or any treatments (p =
0.082).
HE3286 Counters the Influence of Elevated
IOP Throughout the Optic Projection
Brain-Derived Neurotrophic Factor (BDNF)
Deficits in anterograde transport to the SC of glaucomatous mice
is accompanied by significant changes in local neurochemistry,
including increased localization of BDNF (Crish et al., 2013).
Within the SC of vehicle rats, BDNF also appeared to
increase with microbead-induced elevated IOP (Figure 3A, left);
treatment with HE3286 (20 mg/kg) appeared to blunt this
increase (Figure 3A, right). In the optic nerve head (ONH;
Figure 3B), which is a major site of stress in glaucoma
(Hernandez, 2000), levels of BDNF appeared similar in saline-
andmicrobead-injected eyes from vehicle treated rats. Treatment
with HE3286 (20 mg/kg) appeared to increase BDNF in the ONH
of microbead-injected eyes compared to saline. Finally, levels
of BDNF in the retina decreased following microbead injection
in vehicle-treated rats, with HE3286 again blunting this effect
(Figure 3C).
When quantified (Figure 3D), the ratio of BDNF in
microbead to saline SC for vehicle rats was significantly greater
than an expected ratio of unity: 2.34 ± 0.12 (p < 0.001). This
ratio was diminished by 70% compared to vehicle in the 20mg/kg
HE3286 group (0.71 ± 0.09; p < 0.001) and by 43% in the 100
mg/kg group (1.34 ± 0.08; p < 0.001). In the ONH (Figure 3D,
middle), the ratio of microbead to saline BDNF increased with
20 mg/kg HE3286 by 69%: 1.43± 0.20 vs. 0.84± 0.16 for vehicle
(p = 0.042). The 34% increase in this ratio for the 100 mg/kg
dose was not significant compared to vehicle (0.93 ± 0.12; p =
0.66). Finally, in the retina, treatment with HE3286 increased
the microbead:saline ratio of BDNF by 282% in the 20 mg/kg
group (0.64 ± 0.05) and by 501% in the 100 mg/kg group (1.00
± 0.05) when compared to vehicle (0.17 ± 0.04; p < 0.002);
the 100 mg/kg HE3286 ratio was significantly below an expected
ratio of unity (p = 0.02). Thus, as microbead-induced elevations
in IOP degrade anterograde transport in the optic projection,
HE3286 treatment generally has the effect of opposing the change
in BDNF levels induced by elevated IOP.
Note that for BDNF and all other immunolabeled proteins we
quantified, the total SC area for saline (7.013 ± 0.006 mm2) and
microbead (7.017 ± 0.003 mm2) eyes or vehicle (7.019 ± 0.002
mm2) and HE3286 groups (7.012 ± 0.005 mm2) did not vary
(p ≥ 0.088). Similarly, total area quantified in the nerve head
did not vary between saline (7.019± 0.002 mm2) and microbead
(7.022 ± 0.002 mm2) eyes or between vehicle (7.018 ± 0.003
mm2) and HE3286 groups (7.022 ± 0.002 mm2; p > 0.279).
Finally, total area quantified in the retina was similar between
saline (2.756± 0.203 mm2) and microbead (2.712± 0.198 mm2)
eyes or between vehicle (2.996± 0.204 mm2) and HE3286 (2.603
± 0.199 mm2; p> 0.076) groups.
Microglia Activation
Given HE3286’s proposed anti-inflammatory action and the
contribution of microglia as neuroinflammatory mediators in
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FIGURE 1 | HE3286 treatment does not lower ocular pressure following microbead occlusion. (A) Mean intraocular pressure (IOP) in rats before (day 0) and
following (days ≥1) a single unilateral injection of polystyrene microbeads (5.0 µl) into the anterior chamber. The fellow eye was injected with an equivalent volume
saline. (B) Microbead-injected eyes exhibited an increase in IOP following injection (mean ± SEM shown) compared to saline eyes, regardless of treatment. *p ≤
0.002, n = 6 per treatment group.
glaucoma, we examined how treatment influences levels of
ionized calcium-binding adapter molecule 1 (Iba1), a microglia-
specific marker (Ito et al., 1998; Soto and Howell, 2014; Mac Nair
and Nickells, 2015). In the SC, microbead-induced elevated IOP
elicited a modest increase in Iba1 levels in vehicle animals, which
was mitigated by HE3286 (Figure 4A). In the ONH, elevated
IOP sharply increased Iba1, which again was prevented in the
HE3286 group (Figure 4B). Iba1 appeared elevated in microbead
retina from vehicle-treated rats, while treatment with HE3286
had the opposite effect (Figure 4C). The influence of HE3286 was
significant in all three tissues (Figure 4D). Treatment with the 20
mg/kg dose of HE3286 reduced the ratio of Iba1 in microbead
to saline SC by 63%: 0.84 ± 0.11 compared to 1.29 ± 0.19 for
vehicle (p = 0.037). The 100 mg/kg dose had a similar influence
(0.86 ± 0.17, p = 0.061). The microbead:saline ratio of Iba1 in
ONH for vehicle rats was significantly greater than an expected
ratio of unity: 1.56± 0.12 (p= 0.045). This ratio was diminished
by 83% in the 20 mg/kg HE3286 group (0.27 ± 0.03; p = 0.005);
100mg/kg HE3286 had far less effect (1.09± 0.27; p= 0.193). For
vehicle retina, the Iba1 microbead to saline ratio was significantly
more than 1 (1.42 ± 0.04; p = 0.007). Treatment with both 20
mg/kg and 100 mg/kg HE3286 decreased this ratio compared to
vehicle: 1.09 ± 0.08 for the 20 mg/kg group (p = 0.018) and 0.99
± 0.07 (p= 0.009) for the 100 mg/kg group.
Markers of Neuroinflammation or Neurodegeneration
Other significant markers implicated in neuroinflammation or
neurodegeneration were also modulated in the optic projection
by HE3286. Interleukin 6 (IL6) is a pro-inflammatory cytokine
that can promote RGC survival (Matousek et al., 2012; Song
et al., 2013). In the SC of vehicle rats, IL6 localization appeared
to diminish with elevated IOP; this was reversed with HE3286
(Figure 5A). The p75 neurotrophin receptor is a member of the
tumor necrosis factor receptor family and has diverse roles in
neuronal activity, plasticity, and injury response (Meeker and
Williams, 2015). We found that p75 levels increased within
the ONH of microbead eyes from vehicle rats; treatment
with 20 mg/kg HE3286 prevented this increase (Figure 5B).
Finally, amyloid precursor protein (APP) is cleaved to form
β-amyloid, a major component of amyloid plaques. Recent
evidence suggests this protein and its cleaved products may
be involved in the pathogenesis of glaucoma (Jain and Aref,
2015). HE3286 appeared to increase APP levels in saline-injected
eyes (Figure 5D). We found that microbead-induced elevations
in IOP increased APP in the optic nerve head (Figure 5C)
and retina (Figure 5D) of vehicle rats. In both tissues, HE3286
prevented this increase.
When quantified (Figure 5E), the ratio of IL6 in microbead
to saline SC was significantly less than an expected value of
unity: 0.55 ± 0.08 (p = 0.005). This trend was reversed by 100
mg/kg HE3286, which increased the IL6 ratio by 219% compared
to vehicle: 1.75 ± 0.51 (p = 0.047). In the ONH (Figure 5F),
the microbead to saline ratio for p75 was also significantly
higher than unity: 2.41 ± 0.15 (p = 0.011). Treatment with
both 20 mg/kg and 100 mg/kg HE3286 prevented the increase
with elevated IOP, reducing the ratio by 58% (1.02 ± 0.14; p =
0.002) and 66% (0.82 ± 0.14; p = 0.001), respectively, compared
to vehicle. For APP in ONH (Figure 5G), treatment with 20
mg/kg HE3286 decreased the microbead to saline ratio by 53%
compared to vehicle: 5.71 ± 1.15 vs. 12.13 ± 1.49 (p = 0.027).
Similarly, 100 mg/kg HE3286 elicited a 54% decrease to 5.63
± 0.84 (p = 0.019). In the retina (Figure 5H), elevated IOP
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FIGURE 2 | HE3286 treatment rescues axonal transport following microbead occlusion. (A) Coronal sections (top row) through the superior colliculus
following intravitreal injection of CTB (green) into saline- and microbead-injected eyes of vehicle- and HE3286-treated rats. Deficits in anterograde transport of CTB
(dotted lines) due to microbead-induced elevations in IOP are most apparent in vehicle rats. Representation of the optic disc in the retina (OD) lacks transport due to
absence of RGCs. Retinotopic maps (bottom row) reconstructed from serial sections of SC with optic disc indicated (circles). Density of the transported CTB signal
ranges from 0% (blue) to 50% (green) to 100% (red). Medial (M) and rostral (R) orientations are indicated. Scale: 500 µm. (B) Intact transport for individual saline- and
microbead-injected eyes per treatment group given as fraction of SC retinotopic map with CTB signal ≥70% of the maximum. Two SCs from saline-injected eyes of
vehicle-treated rats and one SC from a saline-injected 20 mg/kg HE3286-treated rat were excluded from analysis due to lack of CTB uptake by RGC. (C) Mean level
of intact transport in SC was reduced by elevated IOP in vehicle group compared to saline eye (*p = 0.003). Higher dose of HE3286 prevented this reduction (**p =
0.025). n = 4–6 animals per treatment group.
significantly increased the microbead to saline ratio for APP
well above an expected ratio of unity: 8.05 ± 0.81 (p = 0.013).
Treatment with HE3286 significantly decreased the ratio by 97
and 94% for the 20 mg/kg and 100 mg/kg doses, respectively,
compared to vehicle (p <0.001). Both the ratio for 20 mg/kg
HE3286 (0.25± 0.05) and 100 mg/kg HE3286 (0.48± 0.14) were
significantly lower than unity (p ≤ 0.035).
As with BDNF (Figure 3) and Iba1 (Figure 4), in each of the
cases illustrated in Figure 5, treatment with one or both doses
of HE3286 tended to oppose the action of elevated IOP in the
vehicle cohort, as indicated by the directionality of the change
in the microbead:saline ratio for each. If the ratio >1 in vehicle
tissue, HE3286 treatment pushed the ratio below unity; if the
vehicle ratio <1, HE3286 increased the ratio above unity. This
tendency held for other proteins we tested in SC, ONH, and
retina and for which HE3286 elicited a significant change in
expression level. These results are summarized in Table 3.
HE3286 Modulates Common Pathogenic
Markers for Glaucoma in the Retina
Next we examined howHE3286 treatment influences localization
of common markers for neurodegeneration in glaucomatous
retina. Ceruloplasmin (Cp) is a positive acute phase protein
upregulated during inflammation (Denko, 1979; Goldstein
et al., 1979). In vehicle retina, Cp increased dramatically
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FIGURE 3 | HE3286 treatment influences BDNF levels in optic projection. Confocal micrographs of saline- and microbead-eye tissue from vehicle and HE3286
rats show immunolabeling for BDNF in superior colliculus (SC, A), optic nerve head (ONH, B), and retina (Ret, C), which also shows RGCs labeled by CTB uptake.
Dotted lines indicate region of retina where immunolabel was quantified. Scale: 50 µm (A,B) and 20 µm (C). (D) Bar graphs indicate quantification of levels of BDNF in
superior colliculus (SC), optic nerve head (ONH), and retina expressed as the microbead:saline ratio for vehicle and HE3286 treatment groups. † Indicates significant
departure from expected ratio of unity (p ≤ 0.02), which is indicated (dotted line). *indicates p ≤ 0.042 compared to ratio for vehicle group. n = 6 animals per vehicle
treatment group, 5 animals per 20 mg/kg and 100 mg/kg HE3286 groups for SC; n = 3 animals per treatment group for ONH and retina analysis.
with microbead-induced elevated IOP; HE3286 prevented
this increase (Figure 6A). Interleukin 1β (IL1β) is a pro-
inflammatory cytokine that can promote neurodegeneration
or protection depending on whether the injury is acute or
chronic (Matousek et al., 2012; Song et al., 2013). In vehicle
retina, IL1β decreased with elevated IOP (Figure 6B, left). While
treatment with 20 mg/kg HE3286 further reduced expression
(images not shown), 100 mg/kg HE3286 reversed this trend
(Figure 6B, right). In vehicle retina, elevated IOP appeared
to increase expression of C1q, an early component of the
classical complement pathway, especially in CTB-labeled RGCs
(Figure 6C, left). This too was prevented by 100 mg/kg HE3286
(Figure 6C, right). Finally, we also tested localization of choline
acetyltransferase (ChAT), a marker for cholinergic amacrine
cell neurons, to determine if HE3286 affects levels of common
proteins not typically associated with glaucoma progression.
Neither elevated IOP nor treatment appeared to influence
localization levels (Figure 6D), which were consistent with other
studies (Kang et al., 2004; Feng et al., 2006; Samuel et al., 2011).
When quantified, the ratio of Cp in microbead to saline retina
in the vehicle group was well above an expected value of unity:
4.61 ± 0.49 (p = 0.018; Figure 6E). Treatment with HE3286
abated this increase by 80% compared to vehicle in the 20 mg/kg
group (0.92 ± 0.29; p = 0.003) and by 96% in the 100 mg/kg
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FIGURE 4 | HE3286 treatment influences Iba1-labeled microglia in optic projection. Confocal micrographs of saline- and microbead-injected tissue from
vehicle and HE3286 rats show immunolabeling for the microglia marker Iba1 in superior colliculus (SC, A), optic nerve head (ONH, B), and retina (Ret, C), which also
shows RGCs labeled by CTB uptake. Dotted lines indicate region of retina where immunolabel was quantified. Scale: 50 µm (A,B) and 20 µm (C). (D) Bar graphs
indicate quantification of Iba1 in superior colliculus (SC), optic nerve head (ONH), and retina expressed as the microbead:saline ratio for vehicle and HE3286 treatment
groups. † indicates significant departure from expected ratio of unity (p ≤ 0.045), which is indicated (dotted line). *Indicates p ≤ 0.037 compared to ratio for vehicle
group. n = 6 animals per vehicle treatment group, 5 animals per 20 mg/kg and 100 mg/kg HE3286 groups for SC; n = 3 animals per treatment group for ONH and
retina analysis.
group (0.18 ± 0.03; p < 0.001). For IL1β (Figure 6F), elevated
IOP significantly reduced levels compared to saline retina in
the vehicle group, yielding a ratio of 0.28 ± 0.02 (p = 0.001).
Treatment with 20 mg/kg HE3286 further reduced IL1β by 76%
(0.07 ± 0.04; p = 0.009). However, 100 mg/kg HE3286 had the
opposite effect, increasing levels by 440% compared to vehicle
(1.49± 0.14; p= 0.001). Elevated IOP in vehicle rats significantly
increased levels of C1q compared to saline retina: 1.225 ± 0.061
(p = 0.033, Figure 6G). While 20 mg/kg HE3286 had little effect
(1.430 ± 0.096), 100 mg/kg HE3286 significantly reduced the
C1q microbead to saline ratio compared to vehicle: 0.037 ±
0.007 (p < 0.001). As expected, levels of ChAT were the same in
saline and microbead retinas in all treatment groups (Figure 6H,
p ≥ 0.461).
HE3286 Changes NFκB Localization in the
Optic Projection
One proposed mechanism of action for HE3286 is to modulate
the transcription factor NFκB, which translocates to the
nucleus when activated (Offner et al., 2009). Using an
antibody with proven efficacy in brain (Herkenham et al.,
2011; Figure 7A), we examined and quantified the degree of
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FIGURE 5 | HE3286 treatment influences other degenerative markers in optic projection. Confocal micrographs of saline- and microbead-injected tissue
from vehicle and HE3286 rats show immunolabeling for IL6 in superior colliculus (SC, A), p75 in optic nerve head (ONH, B), and APP in optic nerve head (ONH, C)
and retina (Ret, D), which also shows RGCs labeled by CTB uptake. Dotted lines indicate region of retina where immunolabel was quantified. Scale: 50 µm (A–C) and
20 µm (D). Bar graphs (E–H) indicate quantification of each of these markers in the specified tissue expressed as the microbead:saline ratio for vehicle and HE3286
treatment groups. SC: superior colliculus; ONH: optic nerve head. † Indicates significant departure from expected ratio of unity (p ≤ 0.047), which is indicated (dotted
line). *indicates p ≤ 0.027 compared to ratio for vehicle group. n = 6 animals per vehicle treatment group, 5 animals per 20 mg/kg and 100 mg/kg HE3286 groups for
SC; n = 3 animals per treatment group for ONH and retina analysis.
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TABLE 3 | Significant HE3286-induced changes in expression compared to vehicle.
Target Tissue Vehicle (p-value) 20 mg/kg 100 mg/kg p-values
TNFα ONH 1.68 ± 0.20 (0.038) 0.28 ± 0.10: 83%↓ No change 0.003
IL6Rαm ONH 1.93 ± 0.09 (<0.001) 0.72 ± 0.03: 62%↓ 0.74 ± 0.11: 63%↓ <0.001
IL6 Retina 5.43 ± 0.84 (0.006) 2.10 ± 0.37: 61%↓ 2.55 ± 0.65: 53%↓ ≤0.045
p75 Retina 2.41 ± 0.22 (0.022) 1.53 ± 0.20: 37%↓ 1.26 ± 0.21: 48%↓ ≤0.041
CD44 Retina 1.32 ± 0.10 No change 0.48 ± 0.11: 63%↓ 0.005
Aβ Retina 8.89 ± 0.58 (<0.001) 13.19 ± 1.33: 48%↑ 5.02 ± 0.88: 44%↓ ≤0.042
Tissue expression given as microbead:saline, mean ± SEM (n = 3 animals per groups). Vehicle p-value indicates significance for ratio compared expected value of unity. ONH, optic
nerve head; IL6, interleukin-6; p75, low-affinity neurotrophin receptor; CD44, homing cell adhesion glycoprotein; TNFα, tumor necrosis factor α; IL6Rαm, membrane bound IL6 receptor
α; Aβ, beta-amyloid. ↑, increase compared to vehicle; ↓, decrease compared to vehicle.
nuclear localization of NFκB in SC, optic nerve head, and
retina. In vehicle-treated rats, NFκB localized both within and
external to nuclei in SC; microbead SC appeared to have
less nuclear localization (Figure 7B). Treatment with HE3286
increased NFκB particularly in microbead SC. Within the ONH
(Figure 7C), microbead-induced elevations in IOP increased
NFκB in nuclei for the vehicle group; this was prevented with
HE3286 treatment. In retinal sections (Figure 7D), elevated
IOP had little effect on NFκB localization. However, HE3286
appeared to increase NFκB translocation, particularly in RGCs
of microbead retina.
Using an established algorithm (Carmona et al., 2007;
Schneider et al., 2012), we quantified the degree of nuclear
localization of NFκB as the ratio of levels in tissue from
microbead to saline eyes (Figures 7E–G). For SC (Figure 7E),
this ratio was significantly lower than an expected value of 1
for vehicle rats (p = 0.006), consistent with our qualitative
observation (Figure 7B). Treatment with HE3286 reversed this
trend as we found that the ratio of microbead to saline nuclear
NFκB increased 77% (1.25 ± 0.09) in rats treated with 20 mg/kg
HE3286 and by 39% (0.99± 0.09) in rats treated with 100 mg/kg
HE3286; both changes were significant compared to vehicle (0.71
± 0.5; p ≤ 0.031). In the ONH (Figure 7F), NFκB in nuclei
increased significantly with microbead elevations in IOP for the
vehicle group (1.50 ± 0.18; p = 0.047). Treatment with 100
mg/kg HE3286 decreased the ratio of microbead to saline levels
by 35% (0.97 ± 0.12), which was significant compared to vehicle
(p = 0.038). Treatment with 20 mg/kg HE3286 had little effect
compared to vehicle (1.41 ± 0.22; p = 0.753). Similar to the
SC, nuclear NFκB in the retina increased with IOP elevation for
the HE3286 treatment groups (Figure 7G). Treatment with 100
mg/kg HE3286 caused a 62% increase (1.47 ± 0.14) compared
to the microbead:saline ratio in vehicle (0.90 ± 0.25; p = 0.044);
this was also significantly different from an expected ratio of 1
(p = 0.031). The 20 mg/kg HE3286 dose also increased NFκB
nuclear labeling in microbead retina (1.368± 0.185), but the 51%
increase was not significant both compared to vehicle (p= 0.087)
and to an expected ratio of unity (p= 0.117).
NFκB activation can promote degeneration or survival
depending on the cell type (e.g., glia vs. neurons; Mattson and
Camandola, 2001). In SC from each treatment group, NFκB
localized to nuclei of GFAP-labeled astrocytes (Figure 8A), Iba1-
labeled microglia (Figure 4B), and neurons labeled by NeuN or
pNFH (Figures 8C,D). Whether nuclear localization was glial
or neuronal did not appear to be influenced by elevated IOP
in the vehicle cohort, since SC from saline and microbead
eyes showed both. NFκB localization in neuronal nuclei did
appear to increase with elevated IOP in HE3286-treated rats,
consistent with the overall increase in NFκB we observed earlier
(Figures 7B,E).
Within the ONH, the majority of NFκB appeared to localize
in the cytoplasm surrounding DAPI-labeled nuclei, though
nuclei of some astrocytes (Figure 9A) and microglia (Figure 9B)
contained NFκB. Consistent with the overall increase within the
ONH (Figures 7C,F), microbead-induced elevated IOP appeared
to increase glial NFκB nuclear localization in vehicle rats, which
was attenuated by HE3286. In retina, nuclei of RGCs identified
by CTB uptake and GFAP-labeled astrocytes also demonstrated
NFκB localization (Figures 9C,D). Elevated IOP appeared to
decrease nuclear NFκB in vehicle rats, with HE3286 treatment
reversing this trend. Again, this finding is consistent with
the overall trend of NFκB localization we quantified in retina
(Figures 7D,G).
HE3286 Decreased Retinal Thickness in
Rats with Induced Ocular Hypertension
While examining vertical retinal sections following
immunohistochemistry, we noted what appeared to be a
decrease in retinal thickness within the mid-peripheral region
of the retina in rats treated with HE3286 compared to vehicle
(Figure 10A). To examine this further, we measured retinal
thickness across groups and retinal locations. Comparing mean
retinal thickness (Figure 10C) showed that for vehicle-treated
and 20 mg/kg HE3286-treated rats, retinal thickness was
decreased in microbead-injected eyes compared to saline-
injected eyes, but this difference was not significant (vehicle:
132.51 ± 1.47 vs. 130.93 ± 1.99 µm, p = 0.557; 20 mg/kg dose:
116.35 ± 2.50 vs. 111.47 ± 2.11 µm, p = 0.21). In contrast,
rats treated with 100 mg/kg HE3286 had significantly thinner
retinas in saline-injected eyes (87.70 ± 0.59 µm) compared
to microbead-injected eyes (96.91 ± 0.98 µm; p = 0.001).
Comparing saline-injected eyes across the groups showed that
treatment with HE3286 decreased retinal thickness 12–34%
compared to treatment with vehicle (p < 0.005). Similarly,
retinal thickness decreased 15–26% in microbead eyes treated
with HE3286 compared to vehicle (p < 0.002). Retinal thinning
was dependent on dosage, as a 13–25% decrease was observed
in eyes that received 100 mg/kg HE3286 compared to 20 mg/kg
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FIGURE 6 | HE3286 treatment influences retinal expression of common pathogenic markers. Confocal micrographs of saline- and microbead-injected from
vehicle and HE3286 rats show immunolabeling in retina (Ret) for ceruloplasmin (Cp, A), interleukin 1β (IL1β, B), and C1q, the first component of the classical
complement pathway (C). Localization of amacrine cell neurons specific for ChAT (choline acetyltransferase) is shown for comparison (D). CTB-labeled RGCs are
shown in each panel. Dotted lines indicate region of retina where immunolabel was quantified. Scale: 20 µm (A,B,D) or 10 µm (C). Bar graphs (E–H) indicate
quantification of each of these markers expressed as the microbead:saline ratio for vehicle and HE3286 treatment groups. † Indicates significant departure from
expected ratio of unity (p ≤ 0.037), which is indicated (dotted line). *indicates p ≤ 0.033 compared to ratio for vehicle group. n = 3 animals per treatment group.
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FIGURE 7 | HE3286 modulates NFκB nuclear localization in the optic projection. (A) Confocal micrograph of a coronal section through naïve rat SC shows
localization of NFκB (green) both outside and within DAPI-labeled nuclei (blue). Lines indicate location of orthogonal rotations through nuclei. Scale: 10 µm.
Representative images (single optical plane) of superior colliculus (SC, B), optic nerve head (ONH, C) and retina (Ret, D) from vehicle and HE3286 rats shows
localization of NFκB (green) both within (arrows) and external to (arrowhead) DAPI-stained nuclei. INL: inner nuclear layer of retina; GCL: ganglion cell layer. Scale: 10
µm. Bar graphs show nuclear localization of NFκB in SC (E), optic nerve head (ONH, F), and retina (G) expressed as the ratio of microbead:saline in vehicle and
HE3286 treated tissue; ratio of 1, or unity, indicated by dotted line. † Indicates significant departure from expected ratio of unity (p ≤ 0.026). *Indicates p ≤ 0.044
compared to ratio for vehicle group. n = 5 animals per treatment group.
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FIGURE 8 | NFκB localizes to both neuronal and glial nuclei in superior colliculus. Representative confocal images of NFκB in the superior colliculus (SC) of
vehicle- and HE3286-treated rats with all nuclei indicated (DAPI). Sections were also labeled for astrocytes (A, GFAP), microglia (B, Iba1), or neurons using antibodies
against either NeuN (C) or phosphorylated neurofilament heavy (pNFH; D). Representative nuclei from each cell class demonstrated NFκB localization (arrows). Insets
(solid white, B) show region contained within dashed box with red channel removed to better visualize nuclear localization of NFκB. Scale: 10 µm.
(p < 0.003). To determine if retinal thinning involved neuronal
loss, we counted RGCs that were positive for CTB uptake and
DAPI nuclear labeling and measured the thickness of the inner
nuclear and outer nuclear layers of the retinas (Figure 10D).
Treatment with HE3286 did not reduce the number of RGCs in
20 mg/kg (3.14× 10−4 ± 7.77× 10−6 RGCs/µm2) or 100 mg/kg
(3.16× 10−4 ± 7.48× 10−6 RGCs/µm2) HE3296-treated retinas
compared to vehicle-treated retinas (3.14 × 10−4 ± 6.91 × 10−6
RGCs/µm2; p > 0.963). In contrast, HE3286 treatment reduced
INL thickness 16% for the 20 mg/kg dose (14.1 ± 0.2 µm) and
21% for the 100 mg/kg dose (13.2± 0.1µm) compared to vehicle
(16.8 ± 0.3 mm; p < 0.001). This response was dose-dependent,
as 100 mg/kg HE3286 reduced INL thickness a further 6%
compared to 20 mg/kg (p = 0.029). A similar reduction in ONL
thickness was observed at the higher dose of HE3286 (27.1 ± 0.2
µm) compared to vehicle (33.6 ± 0.4 µm) or the 20 mg/kg dose
(33.4± 0.6 µm; p> 0.001)
DISCUSSION
In this study, we examined the therapeutic potential of a sterol
derivative, HE3286, in an inducible model of glaucoma. Daily
oral gavage with either 20 mg/kg or 100 mg/kg HE3286 did
not affect IOP following microbead or saline injection. Even
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FIGURE 9 | NFκB localizes to glial nuclei in optic nerve head and to glial and neuronal nuclei in retina. Representative confocal images of NFκB (green)
localization in DAPI-stained nuclei of astrocytes (A, GFAP) and microglia (B, Iba1) in optic nerve head (ONH) of vehicle- and HE3286-treated rats. Inset in (B) is region
contained within dashed box with red channel removed to better visualize nuclear localization of NFκB. In retina (C,D), NFκB localizes to nuclei of RGCs with CTB
uptake and GFAP-labeled astrocytes within the retina (Ret). Arrows indicate cells positively-identified by specific label. Scale: 10 µm.
so, treatment with HE3286 did have tremendous influence on
outcomes typically associated with IOP-related axonopathy. We
found that HE3286 (1) preserved anterograde axonal transport
of CTB from the retina to the superior colliculus in microbead-
injected eyes, (2) countered the influence of elevated IOP
throughout the optic projection with respect to levels of BDNF,
Iba1 and other proteins associated with neuroinflammation
and neurodegeneration, (3) modulated pathogenic markers of
glaucoma within the retina, (4) increased NFκB localization to
neuronal nuclei in the superior colliculus and retina, and (5)
decreased NFκB localization to glial nuclei in the optic nerve
head.
HE3286 treatment also resulted in weight loss and retinal
thinning. In a safety and pharmacokinetic study, Ahlem et al.
found that HE3286 had no adverse effects in chronic toxicity
studies and was not immunosuppressive (Ahlem et al., 2011).
Male rats that received daily oral gavage of 100 to 400
mg/kg HE3268 consumed less food and gained less weight
than rats treated with vehicle, but showed no corresponding
pathology or other effects on general health (Ahlem et al.,
2011). We observed a similar weight loss (Table 2), with rats
that received HE3286 losing ∼6–10% of their body weight over
the course of the study. We observed no adverse effects to
general health (e.g., piloerection, hunched posture, decreased
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FIGURE 10 | HE3286 treatment decreases retinal thickness. (A) Confocal images of vertical retinal sections from vehicle- and HE3286-treated rats showing CTB
uptake (green), immunolabeling for APP (red), and DAPI-labeled nuclei (blue). All images were captured in the mid-peripheral region of the retina. Dotted lines show
retinal thickness from nerve fiber layer (NFL) to the retinal pigmented epithelial layer (RPE). Scale bar: 30 µm. PRL: photoreceptor layer. (B) Higher magnification of
retinal section with same markers demonstrating how total retinal thickness (RT), inner nuclear layer thickness (INLT) and outer nuclear layer thickness (ONLT) were
measured. RGCs positive for CTB and DAPI (arrows) were counted. Scale bar: 20 µm. ILM: inner limiting membrane. (C) Bar graph showing HE3286 treatment
decreased retinal thickness. *p < 0.005 compared to vehicle; †p < 0.003 compared to 20 mg/kg HE3286; **p = 0.0013; n = 8 images per animal, three animals per
treatment group. (D) Bar graphs showing HE3286 did not reduce RGC number, but did result in thinning of INL and ONL. *p < 0.001 compared to vehicle; †p <
0.029 compared to 20 mg/kg HE3286 for INL thickness. *p < 0.001 compared to vehicle; †p < 0.001 compared to 20 mg/kg HE3286 for ONL thickness. n = 8
images per animal, three animals per treatment group.
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responsiveness, labored breathing, sudden lethargy, changes in
muscle tone) other than weight loss. We did, however, note
thinning of the retina and nuclear layers in rats that received
HE3286 (Figure 10). Retinal thickness in vehicle treated rats
(∼130 µm) was similar to what has been previously reported
(Cavallotti et al., 2001; Jiao et al., 2013). Regardless of microbead
treatment, retinas from rats treated with HE3286 were 12–
34% thinner than rats that received vehicle. This could be
a side effect of sterol treatment, as Razali et. al. reported
reduced retinal thickness in a model of steroid induced ocular
hypertension in rats (Razali et al., 2015). However, HE3286
is not a glucocorticoid or glucocorticoid mimetic, nor does it
bind the glucocorticoid nuclear hormone receptor (Ahlem et al.,
2011), so this explanation is unlikely. Also, HE3286 treatment
did not elevate IOP (Figure 1), which other steroids can do
(Razeghinejad and Katz, 2012).
Loss of retinal neurons can lead to thinning of the retina
and has been observed in many neurodegenerative disorders or
their models, including glaucoma, Alzheimer’s disease, multiple
sclerosis, and Parkinson’s disease (Lee et al., 2014; Vidal-Sanz
et al., 2015; Gupta et al., 2016; Knier et al., 2016a). The retinal
thinning seen following HE3286 treatment is unlikely to be due
to RGC loss, as counts of CTB+/DAPI+ cells (RGCs) in the
ganglion cell layer showed no significant differences between
vehicle- and HE3286-treated retinas. This was not surprising
as RGC soma loss occurs late in the progression of glaucoma
(Buckingham et al., 2008; Calkins, 2012). We did see significant
thinning of the INL and ONLwith HE3286 treatment. This could
be a sign of effective treatment. Interestingly, thickening of the
INL has been noted in multiple sclerosis patients and correlates
with inflammatory disease severity and disease progression
(Saidha et al., 2015; Knier et al., 2016a). This increase in INL
volume is thought to be due to retinal inflammation; reducing
inflammation via immunomodulatory therapy results in thinning
of the INL (Saidha et al., 2015; Knier et al., 2016a,b). HE3286
treatment decreased levels of inflammatory markers in this study
(Figures 4–6,Table 3). Thinning of the INL andONL byHE3286
(Figure 10) may reflect a lower inflammatory response in these
tissues.
In addition to preserving anterograde axonal transport
(Figure 2), HE3286 also mitigated other indicators of
dysfunction. For example, treatment with HE3286 resulted
in a lack of BDNF elevation in the SC (Figures 3A,D). In
a previous study, we observed focal increases in BDNF in
regions of the SC where anterograde transport was depleted
due to elevated IOP (Crish et al., 2013). Upregulation of
BDNF in glaucoma is likely to result from retinorecipient
targets responding to glaucoma-relevant stress to improve
RGC survival (Chen and Weber, 2004; Lebrun-Julien and
Di Polo, 2008; Weber et al., 2010). HE3286’s preservation of
anterograde transport prevented the need to increase BDNF in
the SC, implying that restoration of RGC function (i.e., axonal
transport) arrests the complex downstream cascades of gliosis
and neuroinflammation normally observed in this condition.
Conversely, HE3286 treatment also increased BDNF in the ONH
and retina (Figures 3B–D). Neurotrophic factor deprivation
due to impaired neurotrophin transport from the brain to the
retina is a longstanding hypothesis in the pathogenesis of RGC
degeneration in glaucoma (Johnson et al., 2011). Increased
BDNF in the optic nerve and retina with IOP elevations suggests
that HE3286 acts on the neurotrophin system, either directly,
or indirectly by increasing transport, to preserve RGCs (Crish
et al., 2013). Whether HE3296 increases BDNF by affecting the
trafficking of BDNF or by stimulating local production of BDNF
in the retina and optic nerve remains to be determined (Johnson
et al., 2011; Crish and Calkins, 2015).
Treatment with HE3286 modulated other proteins implicated
in neuroinflammation or neurodegeneration within the optic
projection (Figures 5, 6, Table 3). For certain proteins, one
dose of HE3286 appeared more effective than the other; this
has been observed previously for HE3286 (Ahlem et al., 2009).
HE3286 may be more effective at regulating signaling pathways
or maintaining homeostasis in a specific tissue at one dose versa
another. Microglia become activated in response to injury and
upregulate a variety of proteins, including Iba1 (Kreutzberg,
1996; Ito et al., 1998; Soto and Howell, 2014; Mac Nair and
Nickells, 2015). Levels of Iba1 were elevated in the SC, ONH,
and retina of vehicle-treated rats; this is not surprising since
microglial activation has been observed in the optic projection
in glaucoma (Wang et al., 2000; Yuan and Neufeld, 2001;
Imamura et al., 2009; Ebneter et al., 2010; Shimazawa et al.,
2012). HE3286 reduced Iba1 expression in all tissues examined,
suggesting it abated microglia activation; a similar effect on
microglia was observed in a model of optic neuritis (Khan
et al., 2014). Treatment with HE3286 also reduced IL6 levels
in the retina and levels of IL6Rαm and TNFα in ONH.
Activated microglia produce these pro-inflammatory proteins
during glaucoma pathogenesis (Tezel et al., 2001; Sappington
and Calkins, 2008; Roh et al., 2012; Sims et al., 2012; Cueva
Vargas et al., 2015; Wilson et al., 2015), so it’s not unexpected that
HE3286 would curb their expression in our model. Interestingly,
HE3286 increased levels of IL6 within the SC and IL1β in the
retina. While associated with neuroinflammation and implicated
in neurodegeneration, both IL6 and IL1β have been shown
to be neuroprotective under certain conditions (Sappington
et al., 2006; Biber et al., 2008; Chidlow et al., 2012; Matousek
et al., 2012; Noguchi et al., 2013; Song et al., 2013; Madeira
et al., 2015; Wilson et al., 2015). HE3286 also increased APP
levels in saline-injected eyes (Figure 5D). HE3286 is a synthetic
derivative of a DHEA metabolite (Ahlem et al., 2011). DHEA
levels have been linked to Alzheimer’s disease, but the exact
role of this neurosteroid in disease progression is currently
under debate (Kim et al., 2003; Naylor et al., 2008; Aldred and
Mecocci, 2010; Hampl and Bicikova, 2010; Rasmuson et al.,
2011). DHEA treatment was neuroprotective in a rat model
of AD, and in vitro DHEA increases the expression of APP
and its cleavage to non-amyloidogenic fragments (Danenberg
et al., 1996; Aly et al., 2011). It is possible the increase in APP
levels observed in HE3286-treated saline-injected eyes is the
result of DHEA-like APP processing. APP can be neuroprotective
in some cases (Yankner et al., 1989; Schubert and Behl, 1993;
Mucke et al., 1994; Allinquant et al., 1995; Zheng and Koo,
2011). Future studies could include elucidating the effects of
HE3286 on APP and its processing in glaucoma and other
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neurodegenerative diseases. Finally, HE3286 decreased APP
and p75 in the ONH and retina, and dramatically reduced
ceruloplasmin and C1q expression in the retina of microbead-
injected eyes. Each of these factors has been implicated in RGC
death, or has been shown to be elevated in the retina and
optic nerve in human glaucomatous tissue and/or in models
of glaucoma (Stasi et al., 2006, 2007; Goldblum et al., 2007;
Stevens et al., 2007; Wei et al., 2007; Lebrun-Julien et al.,
2009; Kipfer-Kauer et al., 2010; Howell et al., 2011, 2014; Ding
et al., 2012; Meeker and Williams, 2015). Taken as a whole, it
appears HE3286 mitigates the neuroinflammatory response by
dampening microglial activation.
The expression of TNFα, IL6, APP in neurons and glia,
as well as the production of β-amyloid, and the activation of
microglia can all be regulated by NFκB activation (Mattson and
Camandola, 2001; Camandola and Mattson, 2007). A suggested
mechanism of action for HE3286 is the regulation of NFκB
activity (Auci et al., 2007; Ahlem et al., 2009, 2011; Offner
et al., 2009). NFκB is a transcription factor activated by a
wide range of stimuli that in turn regulates the expression of
genes involved inflammation, immune response, cell survival
and cell death (Gilmore, 2008; Hayden and Ghosh, 2008;
Lawrence, 2009). Activated NFκB translocates to the nucleus,
and we observed nuclear localization of NFκB in neurons
and glia within the optic projection of vehicle- and HE3286-
treated rats following IOP elevation (Figures 7–9). Similar
activation of NFκB in the visual pathway has been observed
following injury and in models of glaucoma (Choi et al.,
1998; Agapova et al., 2006; Haenold et al., 2014). Treatment
with HE3286 increased NFκB localization in neuronal nuclei
within the SC and retina and decreased NFκB localization
in ONH glial nuclei in microbead-injected eyes. This cell-
specific NFκB activation may explain the beneficial outcomes
observed in HE3286-treated rats; NFκB activation in glial
cells promotes neuronal degeneration, while activation in
neurons promotes survival (Mattson and Camandola, 2001;
Camandola and Mattson, 2007). Activated NFκB can enhance
mitochondrial bioenergetics and prevent peripheral neuropathy
in rodent models of diabetes (Saleh et al., 2013). Increased
NFκB localization to RGC nuclei in HE3286-treated microbead-
injected eyes may protect these neurons metabolically (Kong
et al., 2009; Baltan et al., 2010; Lee et al., 2011; Coughlin
et al., 2015; Kleesattel et al., 2015; Fahy et al., 2016), such
that axonal transport is preserved compared to vehicle-treated
eyes (Figure 2). Whether or not HE3286 maintains RGC
functionality could be assessed using outcomes such as visual
evoked potentials, electroretinogram, or two-alternative forced-
choice visual behavioral testing in this or other models of
glaucoma.
HE3286 has produced therapeutic benefits in various models
of inflammatory disease, in a model of Parkinson’s and in clinical
trials for diabetic complications (Auci et al., 2007, 2010; Ahlem
et al., 2009; Offner et al., 2009; Conrad et al., 2010; Lu et al.,
2010; Kosiewicz et al., 2011; Nicoletti et al., 2012; Reading et al.,
2013a,b; Khan et al., 2014). HE3286 has been well tolerated
and has presented no adverse effects in human trials (Reading
et al., 2013a,b). We observed positive therapeutic outcomes
in terms of anterograde axonal transport, the expression of
proteins associated with neuroinflammation, neurodegeneration,
and glaucoma pathogenesis, and NFκB activation. The results
of this study suggest HE3286 provides neuroprotection to
RGCs and their axons, which helps preserve function in these
neurons following exposure to elevated ocular pressure. This
neuroprotection could be due to caloric restriction (Table 2), as
has been observed in a mouse model of glaucoma (Guo et al.,
2016). However, HE3286’s anti-inflammatory activity has been
observed in vitro and in mice without weight loss compared
to vehicle controls, and in humans without caloric restriction
or weight loss (Wang et al., 2010; Reading et al., 2013b).
A matched feeding experimental design would be needed to
understand the potential contribution of reduced caloric intake
in our glaucoma model, but prior evidence in other models
suggest the current results are not predominately a result of
caloric restriction. Glaucoma shares many common features
with other neurodegenerative diseases (Crish and Calkins, 2011;
Mckinnon, 2012; Ghiso et al., 2013; Jindal, 2013; Danesh-Meyer
and Levin, 2015; Jain and Aref, 2015). Given the number of
people currently with or likely to develop glaucoma in the near
future, the commonalities between glaucoma and other age-
related neurodegenerative diseases, and that HE3286 is already
being tested in clinical trials, further studies on HE3286 and
the mechanism of its action in the central nervous system is
warranted.
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